ES2070134T3 - Inhibidores de lisil oxidasa. - Google Patents

Inhibidores de lisil oxidasa.

Info

Publication number
ES2070134T3
ES2070134T3 ES89103247T ES89103247T ES2070134T3 ES 2070134 T3 ES2070134 T3 ES 2070134T3 ES 89103247 T ES89103247 T ES 89103247T ES 89103247 T ES89103247 T ES 89103247T ES 2070134 T3 ES2070134 T3 ES 2070134T3
Authority
ES
Spain
Prior art keywords
oxidase inhibitors
lysil
lysil oxidase
inhibitors
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89103247T
Other languages
English (en)
Inventor
Michael G Palfreyman
Ian A Mcdonald
Philippe Bey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2070134T3 publication Critical patent/ES2070134T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

ESTA INVENCION RELATA LOS INHIBIDORES VERDADEROS DE OXIDASO LYSYLO Y SU UTILIZACION EN EL TRATAMIENTO DE ENFERMEDADES Y CONDICIONES ASOCIADAS CON LA DEPOSICION ANORMAL DE COLAGENO.
ES89103247T 1988-02-25 1989-02-24 Inhibidores de lisil oxidasa. Expired - Lifetime ES2070134T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16036488A 1988-02-25 1988-02-25
US16038288A 1988-02-25 1988-02-25

Publications (1)

Publication Number Publication Date
ES2070134T3 true ES2070134T3 (es) 1995-06-01

Family

ID=26856831

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89103247T Expired - Lifetime ES2070134T3 (es) 1988-02-25 1989-02-24 Inhibidores de lisil oxidasa.

Country Status (17)

Country Link
EP (1) EP0330218B1 (es)
JP (1) JP2772660B2 (es)
KR (1) KR890012641A (es)
CN (1) CN1035497A (es)
AT (1) ATE117549T1 (es)
AU (1) AU618076B2 (es)
CA (1) CA1338647C (es)
DE (1) DE68920757T2 (es)
DK (1) DK89489A (es)
ES (1) ES2070134T3 (es)
FI (1) FI890827A (es)
GR (1) GR3015470T3 (es)
IE (1) IE65553B1 (es)
IL (1) IL89388A (es)
NO (1) NO890801L (es)
NZ (1) NZ228068A (es)
PT (1) PT89839B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009066152A2 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
SG11201707246YA (en) * 2015-03-06 2017-10-30 Pharmakea Inc Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
AU2018226610A1 (en) * 2017-03-02 2019-09-05 Pharmaxis Ltd. Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
WO2024044813A1 (en) * 2022-08-29 2024-03-07 Pharmaxis Ltd. Novel selective inhibitors of lysyl oxidases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2891064A (en) * 1956-05-28 1959-06-16 Dow Chemical Co 3, 3-dichloro-2-methylallylamines
US4454158A (en) * 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
US4650907A (en) * 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
DD246990A1 (de) * 1986-02-26 1987-06-24 Univ Leipzig Verfahren zur herstellung von gamma-chlorallylverbindungen aus polychloralkanen

Also Published As

Publication number Publication date
PT89839A (pt) 1989-10-04
PT89839B (pt) 1994-04-29
AU618076B2 (en) 1991-12-12
CN1035497A (zh) 1989-09-13
GR3015470T3 (en) 1995-06-30
ATE117549T1 (de) 1995-02-15
EP0330218A2 (en) 1989-08-30
KR890012641A (ko) 1989-09-18
NO890801D0 (no) 1989-02-24
FI890827A (fi) 1989-08-26
FI890827A0 (fi) 1989-02-21
NO890801L (no) 1989-08-28
NZ228068A (en) 1991-11-26
JP2772660B2 (ja) 1998-07-02
EP0330218A3 (en) 1992-01-02
AU3016089A (en) 1989-08-31
DE68920757T2 (de) 1995-06-08
IE890612L (en) 1989-08-25
EP0330218B1 (en) 1995-01-25
DE68920757D1 (de) 1995-03-09
DK89489A (da) 1989-08-26
DK89489D0 (da) 1989-02-24
JPH023626A (ja) 1990-01-09
CA1338647C (en) 1996-10-15
IE65553B1 (en) 1995-11-01
IL89388A (en) 1995-03-15

Similar Documents

Publication Publication Date Title
EP0374440A3 (en) Inhibitors of lysyl oxidase
ATE81978T1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
ES2070134T3 (es) Inhibidores de lisil oxidasa.
DE68907569T2 (de) Mittel zur Behandlung oder Vorbeugung von Aids.
ATE238795T1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
ATE48132T1 (de) Isoxazol- und isothiazolderivate.
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
DE69712287T2 (de) Verwendung von Sulbutiamin zur Behandlung von psychomotorischen oder psychointellektuellen Beschwerden
ATE303158T1 (de) Verwendung von beta-interferon zur behandlung der restenose
DE3881377T2 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
DE68902792D1 (de) Mittel zur kosmetischen oder pharmazeutischen verwendung.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
NO900616D0 (no) Fremgangsmaate for fraksjonering av avlinger i industrieltraamateriale.
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
DE59609836D1 (de) Verwendung von zuckertensiden zur behandlung von ledern und pelzen
DE69822628D1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
DE3887137T2 (de) Mittel zur prophylaxe und behandlung einer pankreatischen erkrannkung oder dergleichen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 330218

Country of ref document: ES